Akums Drugs and Pharmaceuticals Limited (AKUMS) AI Stock Analysis

• Market Cap: ₹66.62B
• Dividend Yield: N/A
• Average Volume (3M): 11.50K
• Price to Earnings (P/E): 20.4
• Beta (1Y): 1.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 7,536
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.60
• Shares Outstanding: 157,393,980
• 10 Day Avg. Volume: 12,021
• 30 Day Avg. Volume: 11,497
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 65 Neutral
• Price Target: ₹458.00 ▲(8.20% Upside)

Akums Drugs and Pharmaceuticals Limited shows a solid financial recovery with improved profitability and a strong balance sheet. However, technical indicators suggest a bearish trend, and the valuation is moderate. The absence of a dividend yield and lack of earnings call data limit the overall attractiveness of the stock.

Positive Factors

Profitability Recovery

Akums' return to profitability and improved margins indicate strong operational efficiency, enhancing its competitive position and financial stability.

Strong Balance Sheet

A strong balance sheet with low leverage provides financial flexibility, reducing risk and supporting long-term growth initiatives.

Operational Efficiency

Improved operational efficiency, as indicated by healthy EBIT and EBITDA margins, suggests effective cost management and sustainable profitability.

Negative Factors

Limited Revenue Growth

Modest revenue growth may indicate challenges in market expansion or product adoption, potentially limiting future earnings potential.

Free Cash Flow Growth

Limited growth in free cash flow could restrict the company's ability to invest in new opportunities, affecting long-term strategic initiatives.

Operational Challenges

A decline in EBIT indicates potential operational challenges that could impact profitability and require strategic adjustments.

Akums Drugs and Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Akums Drugs and Pharmaceuticals Limited (AKUMS) is a leading Indian pharmaceutical company specializing in the manufacturing and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Established in 2004, the company operates in various therapeutic segments including cardiology, diabetes, oncology, and more, providing products that cater to both domestic and international markets. AKUMS is known for its commitment to quality and innovation, with a focus on delivering affordable healthcare solutions.

How the Company Makes Money

Akums generates revenue primarily through the sale of pharmaceutical formulations and APIs to both domestic and international markets. The company has a diverse product portfolio that includes prescription medications, over-the-counter products, and specialized treatments across multiple therapeutic areas. Key revenue streams include direct sales to hospitals and clinics, distribution to retail pharmacies, and exports to various countries. Additionally, AKUMS has established partnerships with various healthcare providers and distributors, which enhance its market reach and contribute to its earnings. The company also invests in research and development to create new products, leading to potential future revenue growth.

Akums Drugs and Pharmaceuticals Limited Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.71B	40.20B	34.75B	36.47B
Gross Profit	16.05B	14.37B	11.67B	12.69B
EBITDA	5.29B	1.31B	3.09B	-821.80M
Net Income	3.38B	-40.35M	948.55M	-2.53B
Balance Sheet
Total Assets	41.13B	35.16B	32.67B	30.69B
Cash, Cash Equivalents and Short-Term Investments	5.82B	2.88B	1.50B	1.03B
Total Debt	882.12M	5.65B	6.19B	3.95B
Total Liabilities	10.50B	27.96B	25.43B	24.44B
Stockholders Equity	30.47B	7.09B	7.17B	6.22B
Cash Flow
Free Cash Flow	1.93B	1.87B	-1.52B	-2.26B
Operating Cash Flow	4.65B	4.98B	1.77B	318.54M
Investing Cash Flow	-5.48B	-3.30B	-3.05B	-2.35B
Financing Cash Flow	727.88M	-1.08B	1.25B	2.36B

Akums Drugs and Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 423.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AKUMS, the sentiment is Negative. The current price of 423.3 is below the 20-day moving average (MA) of 423.88, below the 50-day MA of 442.44, and below the 200-day MA of 495.13, indicating a bearish trend. The MACD of -5.61 indicates Negative momentum. The RSI at 44.12 is Neutral, neither overbought nor oversold. The STOCH value of 68.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AKUMS.

Akums Drugs and Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INDRAMEDCO	69 Neutral	₹43.25B	24.75	―	0.95%	6.51%	18.24%
AKUMS	65 Neutral	₹66.62B	20.44	―	―	―	―
BAFNAPH	65 Neutral	₹3.46B	39.47	―	―	-0.77%	2055.99%
WANBURY	64 Neutral	₹7.84B	15.61	―	―	8.92%	-5.56%
BALPHARMA	58 Neutral	₹1.17B	14.41	―	1.64%	-9.07%	5.36%
KOPRAN	57 Neutral	₹6.32B	35.88	―	2.29%	-6.96%	-66.75%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%